Liminal BioSciences Inc. (LMNL)
$8.5
Rating:
Recommendation:
-
| Symbol | LMNL |
|---|---|
| Price | $8.5 |
| Beta | 29.340 |
| Volume Avg. | 0.02M |
| Market Cap | 27.621M |
| Shares () | - |
| 52 Week Range | 3.1-8.5 |
| 1y Target Est | - |
| DCF Unlevered | LMNL DCF -> | |
|---|---|---|
| DCF Levered | LMNL LDCF -> | |
| ROE | 1.11% | Neutral |
| ROA | 1.11% | Neutral |
| Operating Margin | - | |
| Debt / Equity | 5.62% | Neutral |
| P/E | -1.24 | Sell |
| P/B | 1.67 | Strong Buy |
Latest LMNL news
About
Download (Excel)Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company's lead product candidate is fezagepras (PBI-4050), which has been completed Phase I clinical trial for the treatment of idiopathic pulmonary, liver, cardiac, or skin fibrosis with fezagepras or related derivatives and respiratory diseases. It is also developing antagonist candidate programs, including G-protein coupled receptor 84 and Oxo-eicosanoid receptor 1, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.